Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
SriniVas R SaddaDavid SarrafArshad M KhananiRamin TadayoniAndrew A ChangInsaf SaffarKinfemichael GedifDavid T WongPublished in: The British journal of ophthalmology (2023)
In HAWK and HARRIER, greater reductions in maximum SHRM thickness from baseline were observed with brolucizumab compared with aflibercept. Furthermore, the data suggest that SHRM thickness postloading and SHRM thickness variability over time are biomarkers for visual outcomes in patients with nAMD.